What does NewAmsterdam Pharma Company NV (NAMS) Stock have to offer?
Scotiabank raised the price target for the NewAmsterdam Pharma Company NV (NASDAQ:NAMS) stock to “a Sector outperform”. The rating was released on March 14, 2024, according to finviz. The research report from Piper Sandler has initiated the stock to Overweight, with a price target set at $37. The stock was initiated by RBC Capital Mkts, […]
